Clinical trial
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive…
NCT00343109 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00343109 |
|---|---|
| Title | Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer |
| Official title | Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer |
| Lead sponsor | University of Washington, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Other, Procedure |
| Interventions | HER-2/neu intracellular domain protein, leukapheresis, laboratory biomarker analysis, sargramostim, immunologic technique, synthetic tumor-associated peptide vaccine therapy |
| Enrollment | 38 |
| Start date | Mar 1, 2004 |
| Primary completion | Jun 1, 2015 |
| First posted | Jun 22, 2006 |
| Last update posted | Feb 12, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: